Kathleen Corey, MD
Gastroenterology · Boston, MANPI 1326174038
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $68,566 of the $81,212 with a category attached, or 84.4%. 9 manufacturers reported payments, led by Novo Nordisk AS at 43.2% of the total. Among gastroenterology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 46 payments — averaging $1765.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$35K
- E.r. Squibb & Sons, L.L.C.$15K
- Boehringer Ingelheim$14K
- Theratechnologies Inc.$6K
- Intercept Pharmaceuticals, Inc.$5K
- Novo Nordisk$5K
- plus $2K from 3 others
Across 232 payments — averaging $5576.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$801K
- Intercept Pharmaceuticals, Inc.$195K
- Theratechnologies Inc.$144K
- Intercept Pharma Europe Ltd.$91K
- Novo Nordisk AS$41K
- Gilead$16K
- plus $5K from 1 others
What the payments were for
- Consulting fees$68,56684%
- Speaking & faculty fees$890%
- Travel & lodging$11,78415%
- Food & beverage$7081%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 7 | $35,065 |
| E.r. Squibb & Sons, L.L.C. | 15 | $14,972 |
| Boehringer Ingelheim | 13 | $14,179 |
| Theratechnologies Inc. | 2 | $5,500 |
| Intercept Pharmaceuticals, Inc. | 1 | $4,600 |
| Novo Nordisk | 4 | $4,565 |
| Astrazeneca AB | 1 | $2,148 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $156 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Saxenda$3,375
How this compares
$81,212 in reported general payments places this provider in the 95th percentile of 579 gastroenterology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RezdiffraResmetirom | 18 | $89,524 |
| XifaxanRifaximin | 27 | $89,120 |
| Ursodiol | 24 | $5,531 |
| Omeprazole | 25 | $723 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 41 | $532 |
| Spironolactone | 16 | $309 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Boston
- Hiroyuki AiharaBoston$728K
- Jessica AllegrettiBoston$696K
- John LeungBoston$682K
- Ramnik XavierBoston$567K
- Adam CheifetzBoston$512K
- Carlo TraversoBoston$447K
- Tyler BerzinBoston$215K
- Marvin RyouBoston$162K
- Nneka UfereBoston$153K
- Christopher ThompsonBoston$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.